HRX Roundtable - Navigating Device Development: SEED to Exit Conversations-Navigating Device Development: SEED to Exit Conversations

Video Transcription

Video Summary

The video session titled "Navigating Device Development Seed to Exit" features a panel discussion aimed at providing resources and tools for product development, from early NIH funding to potential exit strategies. Panelist Steve Flynn, an experienced commercial disease therapist, offers insights into fundraising, particularly early-stage investment. Erica Diversi, CEO of Sanguina, shares her company's journey from academic partnerships to Series A funding, emphasizing the importance of non-dilutive funding from NIH and prize competitions in their early stages. Another panelist recounts raising significant amounts and eventually selling their company for $160 million. Julia Berlanska leads discussions about technology commercialization and the pivotal role of NIH funding. Key points discussed include the necessity for companies to pivot based on market and regulatory changes, the importance of having a strong leadership team, and strategies for attracting early funding and managing intellectual property. The session concludes with advice on negotiating with universities for IP rights and the typical equity percentages investors expect in funding rounds.

Keywords

device development

fundraising

NIH funding

exit strategies

intellectual property

early-stage investment

technology commercialization

leadership team